The FERGI (NCT01437566) study, which was a randomized, double‐blind, placebo‐controlled, phase II study, in postmenopausal women with HR+, HER2− BC resistant to treatment with an AI in the adjuvant or metastatic setting, found that the addition of the PI3K inhibitor pictilisib to fulvestrant did not significantly improve PFS (6.6 months vs 5.1; hazard ratio, 0.74; 95% CI, 0.52‐1.06; P = 0.096).51 However, toxicity issues limited pictilisib dosing, thereby potentially limiting its efficacy. The gene discussed is ERBB2; the disease is breast cancer.